Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia

Nov  2019

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products

NEW   YORK,    Nov.    14,    2019     (GLOBE   NEWSWIRE)  --     Everest     Medicines, a biopharmaceutical  company  focused  on   developing  and   commercializing transformative pharmaceutical products that  address critical  unmet medical needs for patients in Greater  China and other  parts of Asia, announced today  that  the rst patient has  been  dosed in a double-blind,  randomized, placebo controlled, multi-center Phase 3 clinical  study   to  evaluate  the   ecacy   and   safety  of  etrasimod  for  induction and maintenance of  treatment in subjects with  moderately to  severely   active  ulcerative colitis (UC).


Etrasimod  is   a   next   generation,  once-daily,   oral,   highly  selective  sphingosine  1- phosphate  (S1P)   receptor  modulator  discovered  by  Arena  Pharmaceuticals,   Inc. (Nasdaq: ARNA), and  designed for optimized pharmacology and  engagement of S1P receptor 1, 4 and 5 that  may lead to an improved ecacy  and safety prole. Etrasimod provides systemic and local effects on specic immune cell types  and has the potential to   treat   multiple   immune-mediated  inammatory  diseases   including   UC,  Crohn’s disease, and atopic dermatitis. In December 2017, Arena Pharmaceuticals, Inc. granted Everest  Medicines an  exclusive,  royalty-bearing license to  develop,  manufacture and commercialize etrasimod  in Mainland  China,  Taiwan,  Hong  Kong, Macau   and  South Korea.  Etrasimod is an  investigational compound that  is not  approved for any use  in any country.


“Dosing  our  rst  patient in this  52-week  phase 3 clinical  study  is  an  important step forward   in  the   evaluation  of  etrasimod as  a  novel  therapy  for  UC  patients  with signicant unmet needs  in China,”  said  Sean   Cao,  CEO of  Everest   Medicines.  “The clinical data generated to date  and  the  mechanism of action  suggests that  etrasimod may become a promising novel oral treatment option  for UC patients. We look forward to working with investigators across all clinical sites to complete the study.”


The phase 3 study  will enroll approximately 330  patients with moderate-severe UC in Mainland  China,  South  Korea  and  Taiwan.  The  primary  objective of  this  study  is  to demonstrate the  ecacy   and  safety of  etrasimod,  in  subjects with  moderately  to severely  active  UC.


About Ulcerative Colitis


Ulcerative   colitis   (UC)  is  a  chronic   disease  that   affects  the   large   intestine.  The innermost lining of the  large  intestine becomes inamed and  ulcers may  form  on the surface, which can  cause symptoms such  as frequent bowel movements, diarrhea and bloody stools. The inammation is usually  found  in the rectum and can  include  all or a portion  of the  colon.  Currently available treatment options have  limitations in terms of side effects, patient response, ecacy  and administration.


About Everest Medicines


Everest   Medicines  is  a   biopharmaceutical  company  focused  on   developing and commercializing transformative pharmaceutical products that  address critical  unmet medical needs for patients in Greater  China and other  Asian markets. The management team of Everest  Medicines has  deep  expertise and  an  extensive track  record  of high- quality  clinical  development, regulatory affairs,  CMC, business development and operations both  in China and  with leading  global  pharmaceutical companies. For more information, please visit its website at www.everestmedicines.com.


Contacts:


Media in US and Europe: Mark Corbae

Senior Vice President

Westwicke PR

+1 (203) 682-8288

mark.corbae@icrinc.com



Media in China: Edmond  Lococo Senior Vice President ICR Asia

+86 (10) 6583-7510

edmond.lococo@icrinc.com


info@cbridgecap.com
www.cbridgecap.com
© 2020 CBC Group. All Rights Reserved.